-
Mashup Score: 22Biomarkers for response to TIL therapy: a comprehensive review - 2 month(s) ago
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Adjuvant Systemic Therapy in Melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)? - 3 month(s) ago
Adjuvant (ADJ) systemic therapy has transformed melanoma treatment during the past decade. There are, however, still important unanswered questions that lead to debates on the utility and place of ADJ therapy for melanoma. When ADJ trials are reported, they present a hazard ratio with a significant P-value. This illustrates the relative benefit of the ADJ therapy, but do not give insight into the absolute benefit for an individual patient. Number needed to treat (NNT) expresses the number of patients required to receive an intervention in order to prevent one event of interest.
Source: www.ejcskn.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Cancer vaccines vs Adoptive Cell Therapy - OncoInfo - 6 month(s) ago
Pros and cons of both therapeutic approaches (and some other things).
Source: oncoinfo.itCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Source: link.springer.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 34The features and management of acquired resistance to PD1-based therapy in metastatic melanoma - 6 month(s) ago
Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete respons…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - 6 month(s) ago
And early ctDNA reductions correlated with survival
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27.30.23 Melanoma Guideline - 6 month(s) ago
SITC’s New Clinical Practice Guideline Immunotherapy for Melanoma, V3.0 On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This manuscript is SITC’s first CPG covering immunotherapy indications for cutaneous melanoma as well as rarer subtypes of the disease. Immunotherapy is a standard of care option for both BRAF -wildtype and
Source: contentsharing.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Ask the Expert: Advanced Melanoma Immunotherapy Options - 8 month(s) ago
Hello Inspire members, Thank you for joining in on this Ask the Expert discussion. We will be discussing everything from advanced melanoma to
Source: www.inspire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 7
Emerging Cell-Based Immunotherapies | August 8-9, 2023 | Boston, MA
Source: www.immuno-oncologysummit.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 42Vigorous Intermittent Lifestyle Physical Activity and Cancer Among Nonexercising Adults - 9 month(s) ago
This prospective cohort study evaluates the dose-response association of device-measured daily vigorous intermittent physical activity with incident cancer risk among a large cohort of inactive adults.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
RT @jitcancer: New #JITC review: Biomarkers for response to TIL therapy: a comprehensive review https://t.co/LvHD0jOwHS @Vic_albarran @pbal…